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Purpose: We evaluated the prognostic significance of T3 subtypes and the role of adjuvant radiotherapy in patients with resected 
the American Joint Committee on Cancer stage IIB T3N0M0 non-small cell lung cancer (NSCLC).
Materials and Methods: T3N0 NSCLC patients who underwent resection from January 1990 to October 2009 (n = 102) were 
enrolled and categorized into 6 subgroups according to the extent of invasion: parietal pleura chest wall invasion, mediastinal 
pleural invasion, diaphragm invasion, separated tumor nodules in the same lobe, endobronchial tumor <2 cm distal to the carina, 
and tumor-associated collapse.
Results: The median overall survival (OS) and disease-free survival (DFS) were 55.3 months and 51.2 months, respectively. In 
postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, 
respectively). Patients with endobronchial tumors within 2 cm of the carina also showed better OS and DFS than those in the other 
T3 subtypes (p = 0.018 and p = 0.016, respectively). However, adjuvant radiotherapy did not cause any improvement in survival (OS, 
p = 0.518 and DFS, p = 0.463, respectively). Only patients with mediastinal pleural invasion (n = 25) demonstrated improved OS and 
DFS after adjuvant radiotherapy (n = 18) (p = 0.012 and p = 0.040, respectively).
Conclusion: The T3N0 NSCLC subtype that showed the most favorable prognosis is the one with endobronchial tumors within 2 
cm of the carina. Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.
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Introduction
The role of adjuvant therapy in patients with resected non-
small cell lung cancer (NSCLC) has been evaluated in many 
randomized clinical trials and meta-analyses [1-3]. Although 
complete resection has been consistently considered to be the 
treatment of choice for most NSCLC patients with T3 disease, 
including cases with chest wall invasion, the role of adjuvant 
treatment following complete surgical resection of early-stage 
NSCLC has not been fully established [4-6]. T3N0 NSCLC is a 
heterogeneous group of tumor subtypes. According to the 6th 
edition of the American Joint Committee on Cancer (AJCC) 
staging system, patients with pT3N0 tumors show a better 
5-year survival rate than those with pT2N0 tumors >7 cm (41% 
vs. 35%, respectively), while in patients with T4 tumors with 
additional nodules in the same lobe the 5-year overall survival 
(OS) rate was 31% [7]. In the 7th edition of the AJCC, T3 stage 
includes various subtypes, particularly tumors that measure 
>7 cm and those where at least two tumors are existent in the 
same lobe. These two subtypes have been newly included in 
2010 in the 7th edition of the cancer staging manual of AJCC 
[8]. Surgery is considered the treatment of choice in patients 
with T3N0 NSCLC, and surgical technique has improved with 
time [9]. The survival of pT3 NSCLC patients changes according 
to the completeness of the resection, and a previous study 
reported that the prognosis of patients with completely 
resected tumors was not affected by the depth of invasion, 
even in the presence of rib or parietal pleura invasion [10].
Controversy still exists concerning whether adjuvant 
radiotherapy should be performed for patients with 
postoperative stage T3N0 cancer [2]. Moreover, various 
opinions have been proposed regarding whether the radiation 
field should be limited to the region of the primary tumor 
or extended to the mediastinal lymph node area [4,5]. A 
Surveillance, Epidemiology and End Results (SEER) database 
analysis reported that postoperative radiotherapy was 
efficacious for patients with stage N2 cancer but lowers the 
survival rate of patients with stage N0 and N1 cancer [11,12]. 
However, one of the critical limitations of the previous study, 
due to its retrospective and unmatched design, was that the 
patients who underwent postoperative radiotherapy had more 
risk factors for recurrence [13,14]. Additionally, it has been 
pointed out that some patients might have been subjected to 
radiotherapy with an inappropriate dose or field [11,15].
Here, we evaluated the prognostic significance of T3 
subtypes and the role of postoperative radiation therapy in 
resected stage IIB T3N0M0 NSCLC patients. The study aimed 
to evaluate the prognostic factors for patients who underwent 
resection for stage IIB T3N0M0 NSCLC. First, the prognosis of 
patients was evaluated according to T3 subtype. In addition, we 
focused on evaluating the efficacy of adjuvant radiotherapy. 
Using subgroup analyses, we tried to identify a subgroup of 
patients who might benefit from adjuvant radiotherapy.
Materials and Methods
1. Patients
In the present study, we conducted a multi-institutional 
retrospective analysis of 102 patients with postoperative 
stage T3N0 NSCLC at Wonkwang University Hospital, Wonju 
Severance Christian Hospital, Gangnam Severance Hospital, 
and Shinchon Severance Hospital. The patients had undergone 
resection from January 1990 until October 2009 and were 
selected in accordance with the 7th edition AJCC stage T3N0. 
Before undergoing the operation, each patient underwent 
staging workups such as chest computed tomography (CT) and 
whole-body bone scans. Because the descriptions of T3 tumor 
extent vary, we categorized the patients into 6 subgroups for 
T3 tumors: parietal pleura chest wall invasion, mediastinal 
pleural invasion, diaphragm invasion, separated tumor nodules 
in the same lobe, endobronchial tumor located <2 cm distal 
to the carina, tumor-associated collapse (atelectasis) or 
obstructive pneumonia (Fig. 1). This study was approved by our 
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Fig. 1. Schematic illustration of non-small cell lung cancer. (A) 
Parietal pleura/chest wall invasion. (B) Mediastinal pleural invasion. 
(C) Endobronchial tumor <2 cm distal to the carina. (D) Tumor-
associated collapse (atelectasis) or obstructive pneumonia. (E) 
Separated tumor nodules in the same lobe. (F) Diaphragm invasion.
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Institutional Review Board (IRB No. 3-2011-0164). The median 
follow-up period was 35.9 months.
2. Treatment
Complete resections were performed in all but 5 patients 
(95.1%). When chest wall invasion was preoperatively 
suspected, a chest wall resection, including the affected rib, 
was scheduled. Extrapleural resection was performed when 
the parietal pleura could be easily freed from the chest wall. 
Five patients (4.9%) underwent a complete gross resection 
by thoracotomy but were found to have positive margins on 
the final pathologic review of the resected specimens (R1 
resections). Seventy-six patients (74.5%) manifested pleural 
invasion (parietal pleura/chest wall invasion + mediastinal 
pleural invasion), while 16 (15.7%) were diagnosed with 
an endobronchial lesion within 2 cm of the carina (Table 
1). Adjuvant radiotherapy was administered at 6 or 10 MV 
photons using a linear accelerator in 57 patients (55.9%). The 
median total radiation dose was 54 Gy (range, 45 to 60 Gy). 
The radiation field included the tumor bed without/with the 
mediastinal lymph node areas. The tumor bed was defined as 
the region invaded by the tumor and the surrounding tissue 
(primary tumor bed plus the margin). Platinum-based CT 
agents (docetaxel or paclitaxel + cisplatin) were mainly used as 
an adjuvant treatment.
3. Follow-up and response assessment
The OS was measured between the date of operation and the 
date of death or final observation, and disease-free survival 
(DFS) was measured between the date of operation and the 
date of recurrence. The locoregional relapse-free survival and 
distant metastasis-free survival were also evaluated. Local 
failure was defined as tumor recurrence within the original 
tumor bed. Regional failure was defined as tumor recurrence 
within the ipsilateral hilar, mediastinal, or supraclavicular 
regions. Distant metastasis refers to cancer that has spread 
from the original (primary) tumor to distant organs or distant 
lymph nodes.
For statistical analysis, PASW ver. 18 (SPSS Inc., Chicago, IL, 
USA) was used. The Kaplan-Meier method and the log-rank 
test were used to calculate the survival rate and to compare 
the scores of subgroups, respectively. For multivariate analysis, 
Cox regression was used.
Results
1. Patient characteristics
The median age of the patients was 64 years (range, 37 to 85 
years), and 85 patients (83.3%) were male. The median size 
of the tumors was 5 cm, and 55 patients (55.6%) had tumors 
that measured 5 cm and above. Sixty-nine patients (67.6%) 
had tumors located in the upper lobe. A similar number of 
tumors were present in the left upper lobe (n = 34) and 
right upper lobe (n = 35). The most common T3 subtype was 
pleural invasion, present in 76 patients (74.5%), followed 
by an endobronchial lesion within 2 cm of the carina in 16 
patients (15.7%). The main histologic types were squamous 
cell carcinoma (57.8%) and adenocarcinoma (30.4%). Of 102 
patients, 57 (55.9%) underwent adjuvant radiotherapy. Among 
the patients who underwent radiotherapy (n = 57), 43 patients 
(75.4%) received mediastinal irradiation; eleven of these 
patients had costal pleural invasion (i.e., elective radiotherapy 
to mediastinum). Fifty-two patients (51.0%) received adjuvant 
chemotherapy (Table 2).
Table 1. Patient characteristics (n = 102)
Characteristic No. (%)
Sex (male)
Tumor size (≥5 cm)
Tumor location 
   Left upper lobe
   Right upper lobe
   Right middle lobe
   Right lower lobe
   Left lower lobe
   Right main bronchus
   Left main bronchus
T3 subtype 
   Parietal pleura/chest wall invasion
   Mediastinal pleural invasion
   Same lobe multiple lesions
   Endobronchial lesion, carina <2 cm
   Collapse with obstruction 
   Diaphragm invasion 
Risk factor 
   Lymphovascular invasion
   Vascular invasion
   Resection margin positive
Histological feature
   Squamous cell carcinoma 
   Adenocarcinoma
   Adenosquamous carcinoma 
   Large cell carcinoma 
   Non-small cell lung cancer, others
85 (83.3)
56 (54.9)
 
34 (33.3)
35 (34.3)
 5 (4.9)
13 (12.7)
13 (12.7)
 1 (1.0)
 1 (1.0)
 
51 (50.0)
25 (24.5)
 4 (3.9)
16 (15.7)
 3 (2.9)
 3 (2.9)
 
 6 (5.9)
 7 (6.9)
 5 (4.9)
 
59 (57.8)
31 (30.4)
 4 (3.9)
 2 (2.0)
 6 (5.9)
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2. Survival analysis
The median OS was 55.3 months and the median DFS was 51.2 
months (Fig. 2). The actuarial 4-year loco-regional relapse-
free survival was 49.9%, and the 4-year distant metastasis-
free survival was 53%. The univariate analysis showed that 
OS (p = 0.008) and DFS (p = 0.004) were significantly lower 
in tumors that measured 5 cm and above (Table 3). Patients 
with endobronchial tumors located <2 cm distal to the 
carina showed higher survival rate than other T3 subtypes 
in the univariate analysis (OS, p = 0.003 and DFS, p = 0.006, 
respectively). Also, the patients with pleural invasion showed 
lower survival than other T3 subtypes in the univariate 
analysis (OS, p = 0.023 and DFS, p = 0.049, respectively). On 
multivariate analysis, the OS and DFS were significantly lower 
in tumors that measured ≥5 cm than in tumors <5 cm (p 
= 0.035 and p = 0.035, respectively) (Table 3). The location 
of endobronchial tumors <2 cm distal to the carina was an 
independent prognostic factor for OS and DFS (p = 0.018 and 
p = 0.016, respectively) (Table 3). The survival rate according to 
operation type and extent of resection was analyzed, and no 
statistically significant difference was noted in survival (Tables 
3). The OS showed no significant difference between the 
pneumonectomy group (n = 30) and the lobectomy (n = 64) 
group (p = 0.417 vs. p = 0.601, respectively). Wedge resection 
was performed only on 3 patients and showed high treatment 
failure rates (66.7%). The patients who underwent wedge 
resection showed a lower survival rate (4-year OS, 33.3% and 
4-year DFS, 33.3%, respectively) than the patients treated with 
other types of curative resection. These patients underwent 
wedge resections owing to tuberculosis (n = 2, 2.0%) or 
emphysema (n = 1, 1.0%) or bronchiectasis (n = 1, 1.0%). 
No significant difference was found in OS and DFS between 
patients treated with or without adjuvant chemotherapy (p = 
0.440 and p = 0.619, respectively).
3. Survival implication of T3 heterogeneity
The T3 subtype significantly correlated with patient survival 
in the present study. Table 3 shows significantly low OS 
and DFS in stage T3N0 patients with pleural invasion in 
univariate analysis (p = 0.023 and p = 0.049, respectively). 
Patients with endobronchial tumors within 2 cm of the 
carina also had better survival than patients with other T3 
Table 2. Treatment characteristics (n = 102)
Characteristic No. (%)
Operation type
   Pneumonectomy
   Lobectomy
   Bilobectomy 
   Wedge resection 
   Sleeve lobectomy
Adjuvant radiotherapy
   Radiotherapy
   No radiotherapy
Adjuvant chemotherapy
   Chemotherapy
   No chemotherapy
 
30 (29.4)
64 (62.7)
3 (2.9)
3 (2.9)
2 (2.0)
 
57 (55.9)
45 (44.1)
 
52 (51.0)
50 (49.0)
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Fig. 2. Overall survival (OS) and disease-free survival (DFS) among 
the 102 patients. The median OS was 55.3 months and the median 
DFS was 51.2 months.
Table 3. Univariate analysis (log-rank test) and multivariate analysis (Cox regression) for survival
Variable
Univariate analysis (p-value) Multivariate analysis (p-value)
Overall survival Disease-free survival Overall survival Disease-free survival
Tumor size (≥5 cm vs. <5 cm)
Endobronchial lesion (carina <2 cm)
Pleural invasion
Adjuvant chemotherapy
Adjuvant radiotherapy
Operation type
0.008
0.003
0.023
0.204
0.518
0.734
0.004
0.006
0.049
0.304
0.463
0.692
0.035
0.018
0.461
-
-
-
0.035
0.016
0.550
-
-
-
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subtypes in univariate analysis and multivariate analysis (Table 
3). Regarding the T3 subtype with endobronchial tumors 
within 2 cm of the carina, the tumor size was comparatively 
smaller than that of other T3 subtypes. Though there was no 
significant correlation in multivariate analysis, most patients 
with endobronchial tumors within 2 cm of the carina (10/16, 
62.5%) presented with a tumor <5 cm. 
4. The impact of adjuvant radiotherapy on tumor location 
and radiotherapy
Overall, adjuvant radiotherapy did not improve patient survival 
in the present study (Table 3). However, the patients who 
received adjuvant radiotherapy had more risk factors. Four of 5 
patients (80%) with a positive resection margin and 4 patients 
(66.7%) with lymphovascular invasion received postoperative 
radiotherapy. 
In cases of mediastinal pleural invasion (n = 25), OS and 
DFS were longer in patients treated with postoperative 
radiotherapy than in patients who did not receive radiotherapy 
(n = 18) (OS, p = 0.012 and DFS, p = 0.040, respectively) (Fig. 3). 
Among the patients who had accompanying costal pleura 
invasion and received irradiation (n = 22), a subgroup analysis 
of the radiation field was performed; the survival rate was 
higher in cases where radiotherapy was administered only to 
the costal pleura than in cases where radiotherapy was also 
administered to the mediastinum (OS, p = 0.037 and DFS, p = 
0.009) (Fig. 4). Patients who received radiotherapy only to the 
costal pleura (n = 11) experienced more episodes of recurrence 
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Fig. 3. Postoperative radiotherapy (n = 18) improved (A) overall survival (p = 0.012) and (B) disease-free survival (p = 0.040) in patients 
with mediastinal pleural invasion (n = 25). 
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Fig. 4. In patients who underwent postoperative radiotherapy (PORT) for lesions invading the costal pleura (n = 22), (A) overall survival 
rate (p = 0.037) and (B) disease-free survival (p = 0.009) rate were higher in patients who received PORT only to the costal pleura (n = 
11) than in those who also received PORT to the mediastinum (n = 11).
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(84.6% vs. 55.6%) than those who also received radiotherapy 
to the mediastinum (n = 11); in particular, a higher number 
of distant metastases occurred in patients who received 
radiotherapy only to the costal pleura (72.7% vs. 18.2%).
5. Patterns of failure
Cancer recurred and/or metastasized during follow-up in 39 
patients (38.2%) (Fig. 5). Local recurrence, regional recurrence, 
and distant metastasis were found in 12 cases (11.8%), 11 
cases (10.8%), and 25 cases (24.5%), respectively. The sites of 
distant metastasis were the brain in 10 patients (9.8%), the 
contralateral lung in nine patients (8.8%), and bone in eight 
patients (7.8%). 
Discussion and Conclusion
Gould et al. [5] analyzed the patterns of failure and long-
term outcome for 92 patients with completely resected T3N0 
NSCLC. The local tumor control after resection was excellent; 
only three patients failed locally at 4 years. The actuarial 
4-year local failure-free rate was 94%. The present study 
showed treatment failure in 39 patients (overall recurrence 
rate 38.2%), and local recurrence occurred in 12 cases (11.8%) 
(Fig. 5) [5]. The 4-year actuarial regional failure-free and 
distant failure-free survivals were 74% and 68%, respectively. 
Although the current study showed a higher local recurrence 
rate than Gould’s data [5], the overall recurrence rate was 
similar, and the distant failure-free survival rate was slightly 
lower. The fact that 5 patients with incomplete resection were 
included for this evaluation might influence the results.
For T3N0 NSCLC, the pattern of recurrence may depend 
on the tumor location. Hayakawa et al. [16] reported that 
patients with primary tumors in the upper lobes or the 
superior segment of the lower lobes of the lung lived longer 
than those with primary tumors at any other site. Riquet et 
al. [17] reported that bronchial T3 tumors tended to have a 
better prognosis than T3 tumors infiltrating the mediastinal 
pleura. The present study showed a significantly lower 
survival rate than other subtypes in stage T3N0 patients with 
pleural invasion (OS, p = 0.023; DFS, p = 0.049) in univariate 
analysis. Satoh et al. [18] previously dealt with the influence 
of pleural invasion on the prognosis of patients with lung 
cancer. They held the view that pleural invasion makes cancer 
cells proliferate along the pleural lymphatic flow; as a result, 
prognosis of the patients with pleural invasion might be 
different from the patients with other T3 subtypes. In contrast, 
endobronchial tumors within 2 cm of the carina demonstrated 
a favorable prognosis compared with other T3 subtypes (OS, p 
= 0.003; DFS, p = 0.006).
Several studies have reported that postoperative systemic 
chemotherapy significantly increases the survival rate in 
patients with completely resected NSCLC [1,2]. However, the 
role of adjuvant chemotherapy remains under controversy for 
patients with completely resected T3 NSCLC without nodal 
involvement (T3N0). Lee et al. [19] retrospectively reviewed 
patients with surgically resected NSCLC invading the chest 
wall. They analyzed 107 patients who underwent surgical 
resection for NSCLC with chest wall invasion. They suggested 
that completion of chemotherapy is the only prognostic 
factor for long-term survival in 64 patients (60%) with 
completely resected T3N0 NSCLC infiltrating the chest wall 
[19]. However, no consistent institutional protocol for adjuvant 
chemotherapy existed in our study. As a result, adjuvant 
systemic chemotherapy did not show any significant increase 
in the survival rate in the present study.
The role of adjuvant radiotherapy in T3 NSCLC patients 
with chest wall invasion is still controversial [20-22]. Facciolo 
et al. [23] reported that the overall 5-year estimated survival 
for patients who underwent radiation therapy was 74.1%, 
whereas in patients who did not undergo radiation therapy it 
was 46.7% (p = 0.023). Gould et al. [5] reported a significant 
improvement in locoregional control (p = 0.05) for the use of 
adjuvant radiotherapy in patients with completely resected 
Local recur
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5
Fig. 5. Patterns of failure in resected non-small cell lung cancer 
T3N0 patients (number of patients).
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T3N0 NSCLC. They showed that the 2- and 4-year regional 
control was 100% with radiation therapy compared with 
72% and 68%, respectively, for patients who did not receive 
thoracic radiation therapy. Conversely, Doddli et al. [6] assessed 
prognostic factors in patients with completely resected pT3 
NSCLC infiltrating the chest wall and suggested that adjuvant 
radiotherapy does not seem to be necessary in N0 patients 
when a complete R0 resection was achieved. Owing to the fact 
that the patients selected for adjuvant radiotherapy tended 
to be at risk of relapse, this retrospective study might have 
difficulty in showing a survival advantage for radiotherapy. On 
the other hand, it has been argued that the lower survival rate 
of the patients treated with adjuvant radiotherapy might be 
related to the application of inappropriate radiation dose and 
field [4,5].
According to the present study, adjuvant radiotherapy did 
not cause an improvement in survival for most patients with 
resected T3N0 NSCLC. The radiation-induced pulmonary or 
cardiac toxicities might indirectly affect the survival outcome. 
That is, the poor survival for the patients with adjuvant 
radiotherapy might be associated with the inadequate 
irradiated lung volume and the radiation ports design. In 
contrast, mediastinal postoperative irradiation showed a 
possible survival benefit in the subgroup analysis of patients 
with mediastinal pleura invasion. The tumor extending to the 
mediastinal pleura has a higher possibility to microscopically 
metastasize to the mediastinal lymph nodes. Therefore, 
mediastinal radiotherapy can be effective in the patient 
subgroup with mediastinal pleural invasion. In other words, 
adjuvant radiotherapy to the mediastinal lymph node area may 
be considered to improve survival in the patients with tumors 
involving the mediastinal pleura.
As for the limitations, the patient population of this study 
tended to be heterogeneous. First, it was designed as a multi-
center trial, and variations of treatment among the centers 
might have affected the results. Second, patient enrollment 
was performed within a relatively long period of time (1990–
2009). Technological improvement of radiotherapy (e.g., from 
2-dimensional radiotherapy to 3-dimensional radiotherapy or 
intensity-modulated radiotherapy) during this period could 
decrease the rate of radiation toxicity and it may affect the 
survival rate. In addition, this study did not deal with the 
relationship between the treatment volume of radiotherapy 
and radiation toxicity. In the subgroup evaluation of the 
patients who had accompanying costal pleura invasion and 
received irradiation, the higher survival rate of the patients 
who received treatment only to the costal pleura compared 
to those who also received treatment to the mediastinum 
might be related to the increased radiation toxicity due to 
the enlarged lung irradiation volume. Furthermore, local 
control could be a better end-point than survival to evaluate 
the effect of adjuvant radiotherapy. Last but not least, this 
study is limited by its retrospective design. In particular, the 
univariate subgroup analysis result that adjuvant radiotherapy 
may improve survival in cases of mediastinal pleura invasion, 
should be evaluated in further studies owing to the relatively 
small sample size.
In postoperative T3N0M0 patients, the tumor size was an 
independent prognostic factor. The subtype that showed the 
most favorable prognosis was the one with endobronchial 
tumors within 2 cm of the carina, which had a smaller tumor 
size than other subgroups. When administered after surgery, 
adjuvant radiotherapy is not recommended for most patients 
with T3N0 NSCLC. 
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